Northway Biotech Signs CDMO Deal with Kaida BioPharma for KAD101 Production

• Northway Biotech has entered into a manufacturing agreement with Kaida BioPharma for the clinical production of KAD101.

• The collaboration will support process development and cGMP manufacturing for Kaida’s lead biologic targeting hormone-driven cancers.

Northway Biotech, a contract development and manufacturing organisation (CDMO), has signed a manufacturing agreement with Kaida BioPharma to support clinical production of the biotech firm’s lead candidate, KAD101. The biologic is being developed to target hormone-driven cancers affecting women, with a focus on ovarian cancer.

Under the agreement, Northway Biotech will provide end-to-end support, including analytical method development, formulation optimisation, process development and scale-up. The contract also covers the manufacture of a cGMP drug substance batch for use in clinical studies.

KAD101 is a modified version of a previously tested biologic, G129R, designed to block the prolactin receptor and suppress tumour growth. The company has developed KAD101 as a bi-weekly injectable with a planned Phase 1 clinical trial expected to begin in Q4 2026 or Q1 2027.

“We are incredibly pleased to establish this important partnership with Northway Biotech, a pre-eminent CDMO, to manufacture the clinical drug product necessary for our planned Phase 1 clinical study,” said Craig Pierson, Founder and Chairman of Kaida BioPharma.

Northway Biotech CEO Prof. Vladas Algirdas Bumelis stated that Kaida’s scientific leadership made them “an ideal partner,” as the programme advances toward human trials.

Kaida BioPharma is also developing KAD102, a pure antagonist of KAD101, aimed at treating uterine cancer.